Publications by authors named "C Vancheri"
Baclofen is a common muscle relaxant agent used in a number of neurological disorders acting at central level and potentially causing adverse respiratory events, still largely unknown at therapeutic doses. We present the case of a young woman with spastic tetraparesis secondary to perinatal asphyxia treated with a standard dose of intrathecal baclofen who developed nocturnal symptoms, somnolence and memory loss during the day. Nocturnal cardio-respiratory sleep monitoring showed a high number of central sleep apneas (CSA).
View Article and Find Full Text PDFArticle Synopsis
- Interstitial lung diseases (ILDs) are complex and diverse conditions that affect both children and adults, with limited treatment options and a challenging diagnosis process often requiring invasive techniques.
- The RARE-ILD initiative is a collaborative effort by experts to develop innovative non-invasive diagnostic methods and biomarkers, leveraging artificial intelligence for improved data analysis and understanding of ILDs across different ages.
- The eurILDreg project collects extensive patient data using various assessments and technology, with an aim to enhance research, improve patient care, and potentially revolutionize the management of ILDs for up to 4,000 patients and 100,000 biospecimens.
Progressive pulmonary fibrosis (PPF) has been associated with a worse prognosis, even when interstitial lung disease (ILD) is related to rheumatic diseases. Since many differences are detectable among rheumatic diseases in prevalence and features of ILD, we aimed to investigate features of PPF in different rheumatic diseases, namely rheumatoid arthritis (RA) and primary Sjogren's syndrome (pSS). In an Italian multicentre cross-sectional study, consecutive pSS or RA patients with a diagnosis of ILD from at least two years were enrolled.
View Article and Find Full Text PDF: High-flow nasal therapy (HFNT) has been shown to reduce exacerbations of COPD and some evidence displays benefits in non-cystic fibrosis bronchiectasis (NCFB) patients. The present study aimed to compare the effectiveness of 12 months of home HFNT on the annual exacerbation rate between mild/moderate and severe NCFB patients, classified by the bronchiectasis severity index (BSI). Secondary outcomes were the evaluation of the dyspnea, pulmonary function, and sputum cultures in both groups.
View Article and Find Full Text PDF